ALK and small cell lung carcinoma: In the case report by Li et al., adding an ALK inhibitor to chemotherapy resulted in an OS of more than 27 months, making this case the first reported case of a patient with SCLC with a fusion mutation in the ALK gene who had long-term benefit after treatment with an ALK inhibitor [10].